Merrimack Pharmaceuticals (MACK) Competitors

SAB Biotherapeutics (NASDAQ:SABS) and Merrimack Pharmaceuticals (NASDAQ:MACK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Do insiders & institutionals have more ownership in SABS or MACK?

7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 55.9% of Merrimack Pharmaceuticals shares are held by institutional investors. 31.2% of SAB Biotherapeutics shares are held by insiders. Comparatively, 28.9% of Merrimack Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor SABS or MACK?

Merrimack Pharmaceuticals received 388 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. Likewise, 67.34% of users gave Merrimack Pharmaceuticals an outperform vote while only 66.67% of users gave SAB Biotherapeutics an outperform vote.

Company	Underperform	Outperform
SAB Biotherapeutics	Outperform Votes 12 66.67%	Underperform Votes 6 33.33%
Merrimack Pharmaceuticals	Outperform Votes 400 67.34%	Underperform Votes 194 32.66%

Is SABS or MACK more profitable?

Merrimack Pharmaceuticals has a net margin of 0.00% compared to Merrimack Pharmaceuticals' net margin of -664.68%. SAB Biotherapeutics' return on equity of -7.52% beat Merrimack Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SAB Biotherapeutics	-664.68%	-120.36%	-69.17%
Merrimack Pharmaceuticals	N/A	-7.52%	-7.33%

Which has stronger valuation & earnings, SABS or MACK?

Merrimack Pharmaceuticals has lower revenue, but higher earnings than SAB Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SAB Biotherapeutics	$23.90M	2.13	-$18.74M	N/A	N/A
Merrimack Pharmaceuticals	N/A	N/A	-$1.54M	-$0.10	-126.20

Does the media prefer SABS or MACK?

In the previous week, SAB Biotherapeutics had 5 more articles in the media than Merrimack Pharmaceuticals. MarketBeat recorded 6 mentions for SAB Biotherapeutics and 1 mentions for Merrimack Pharmaceuticals. SAB Biotherapeutics' average media sentiment score of 1.89 beat Merrimack Pharmaceuticals' score of 0.69 indicating that Merrimack Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
SAB Biotherapeutics	Positive
Merrimack Pharmaceuticals	Very Positive

Which has more volatility & risk, SABS or MACK?

SAB Biotherapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500. Comparatively, Merrimack Pharmaceuticals has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500.

Do analysts prefer SABS or MACK?

SAB Biotherapeutics currently has a consensus target price of $1.00, indicating a potential upside of 2.88%. Given Merrimack Pharmaceuticals' higher probable upside, equities research analysts plainly believe SAB Biotherapeutics is more favorable than Merrimack Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SAB Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Merrimack Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Summary

Merrimack Pharmaceuticals beats SAB Biotherapeutics on 9 of the 14 factors compared between the two stocks.